100s of titles, one news app for just $10 a month.
Dive Deeper:
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours:
Fourth Covid vaccine provides 'a substantial boost to immunity', according to new study
Several countries have now deployed fourth doses of the Covid-19 vaccine, but the clinical need, effectiveness, timing, and dose of…
Fourth Covid jab can give higher immunity than initial booster, study finds
UK-based team finds antibodies peaked higher after fourth jab given after gap of more than six months than after third
Mix and match of Covid-19 vaccine for booster shots unlikely to be allowed: Report
As of now, mixing of Covid-19 vaccines is not allowed in the country, which means the precaution dose is of the…
One subscription that gives you access to news from hundreds of sites
Biological E seeks approval of Corbevax as booster for Covishield, Covaxin recipients
Currently, the booster dose being given is of the same Covid-19 vaccine used for administering the first and second doses
Fourth booster ‘significantly’ increases Covid protection
Levels of antibodies waned in period between third jabs and fourth boosters
Get all your news in one place
Latest Technology news:
Jony Ive had one wacky idea for Apple's mixed reality headset
A new report details Apple's internal conflicts over its long-rumored mixed reality headset and the odd features it might ship…
Read news from The Economist, FT, Bloomberg and more, with one subscription
Learn More
Genesis GV60 To Come With 3 Years Of Free Charging On The Electrify America Network
We examine the announcement that Electrify America and Genesis have partnered to offer three years of unlimited charging for Genesis…
Watch Ford's F-150 Lightning Tow A Trailer: How Far Can It Go?
Now that the Ford F-150 Lightning is shipping, we'll get to learn so much more about it from owners and…
'Eiyuden Chronicle: Hundred Heroes' gameplay, trailer, platforms, and story
Rabbit & Bear's highly anticipated Suikoden spiritual successor, 'Eiyuden Chronicle: Hundred Heroes', is coming in 2023. Here's what we know…
Why the Internet Hates Amber Heard
Notes on the paranoid style in online fandom
From analysis to good news, read the world’s best news in one place
22 years later, this cult classic RPG still holds up
22 years ago SquareSoft released 'Vagrant Story', and it still stands out as one of the most influential cult classic…
All the twists and turns in the Musk-Twitter takeover saga
A full breakdown of Musk's remarks, tweets, discussions and dealings in his quest to buy Twitter.

Sanofi-AstraZeneca Say New Nirsevimab Data Reinforce Efficacy Against RSV

By Vandana Singh
  • Sanofi SA (NASDAQ:SNY) and AstraZeneca plc (NASDAQ:AZN) have announced results from a prespecified pooled analysis of nirsevimab in respiratory syncytial virus (RSV).
  • Results from the Phase 3 MELODY and Phase 2b nirsevimab trials demonstrated an efficacy (relative risk reduction versus placebo) of 79.5% against medically attended lower respiratory tract infections due to RSV in infants.
  • In a separate pooled posthoc analysis of the trials, blood samples taken from infants dosed with nirsevimab exhibited RSV neutralizing antibodies that were approximately 50-fold higher than baseline at Day 151 post-dose. 
  • Related: AstraZeneca-Sanofi's Nirsevimab Shows 75% Efficacy Against RSV In Healthy Infants.
  • RSV neutralizing antibody levels remained greater than 19-fold higher than placebo recipients with no known RSV infection through Day 361, suggesting protection may extend beyond Day 151.
  • As reported in previous trials, the safety profile across the nirsevimab and placebo groups remains similar.
  • Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose.
  • Price Action: SNY shares are down 1.36% at $51.46, and AZN stock is down 2.18% at $62.25 during the premarket session on the last check Wednesday.
What is inkl?
The world’s most important news, from 100+ trusted global sources, in one place.
Morning Edition
Your daily
news overview

Morning Edition ensures you start your day well informed.

No paywalls, no clickbait, no ads
Enjoy beautiful reading

Content is only half the story. The world's best news experience is free from distraction: ad-free, clickbait-free, and beautifully designed.

Expert Curation
The news you need to know

Stories are ranked by proprietary algorithms based on importance and curated by real news journalists to ensure that you receive the most important stories as they break.

Dive Deeper:
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours:
Fourth Covid vaccine provides 'a substantial boost to immunity', according to new study
Several countries have now deployed fourth doses of the Covid-19 vaccine, but the clinical need, effectiveness, timing, and dose of…
Fourth Covid jab can give higher immunity than initial booster, study finds
UK-based team finds antibodies peaked higher after fourth jab given after gap of more than six months than after third
Mix and match of Covid-19 vaccine for booster shots unlikely to be allowed: Report
As of now, mixing of Covid-19 vaccines is not allowed in the country, which means the precaution dose is of the…
One subscription that gives you access to news from hundreds of sites
Biological E seeks approval of Corbevax as booster for Covishield, Covaxin recipients
Currently, the booster dose being given is of the same Covid-19 vaccine used for administering the first and second doses
Fourth booster ‘significantly’ increases Covid protection
Levels of antibodies waned in period between third jabs and fourth boosters
Get all your news in one place